Risk talk:: rhetorical strategies in consultations on hormone replacement therapy

被引:11
|
作者
Hoffmann, M
Linell, P
Lindh-Åstrand, L
Kjellgren, KI
机构
[1] Linkoping Univ, Dept Med & Care, Div Clin Pharmacol, SE-58183 Linkoping, Sweden
[2] Linkoping Univ, Dept Commun Studies, SE-58183 Linkoping, Sweden
[3] Linkoping Univ, Dept Mol & Clin Med, Div Obstet & Gynecol, SE-58183 Linkoping, Sweden
[4] Gothenburg Univ, Sahlgrenska Acad, Fac Hlth & Caring Sci, Inst Nursing, SE-40530 Gothenburg, Sweden
关键词
risk; communication; menopause; hormone replacement therapy; physician-patient relations;
D O I
10.1080/1369857031000123920
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
When analysing risk discussions in medical settings it is important to consider the specific activity type. In this qualitative study 20 first-time consultations by healthy women regarding hormone replacement therapy (HRT) in the menopause the risk discussion is asymmetrical with the doctors dominating. Despite being set up as a specific opportunity for women in the menopause to discuss problems and risks, it comes forth as a decision-making activity in a traditional medical setting. The consultations fulfil to a high extent the demands for informed decision making, but the risk discussions are recontextualised into a cost-benefit discourse with a typical implicit quantitative bias. The doctors use several different rhetorical strategies such as positive introduction of HRT, embedding drawbacks in positive introductions and/or exits thereby diminishing them. The word risk is avoided to a considerable extent and the term 'drawbacks' is used instead. The most obvious strategy is to move from the woman's symptoms to aspects of prevention, thus changing the discussion from the menopause and different strategies to cope with menopausal problems into a medically oriented discussion of pharmacological treatment alternatives. The 'change of life' in these talks is entirely conceptualised within a 'medical model'.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 50 条
  • [21] Hormone replacement therapy and risk for neurodegenerative diseases
    Levine, Andrew J.
    Sutton, James
    Singer, Elyse J.
    Miller, Karen J.
    SALUD I CIENCIA, 2008, 16 (02): : 148 - 155
  • [22] Hormone replacement therapy and risk of breast cancer
    Ortmann O.
    Treeck O.
    Inwald E.C.
    Emons G.
    Tempfer C.
    best practice onkologie, 2019, 14 (12) : 570 - 579
  • [23] Hormone replacement therapy and risk of breast cancer
    Ortmann, Olaf
    Treeck, Oliver
    Inwald, Elisabeth C.
    Emons, Guenter
    Tempfer, Clemens
    GYNAKOLOGE, 2019, 52 (08): : 605 - 616
  • [24] Hormone replacement therapy and risk of breast cancer
    Ortmann, O
    Schulz, KD
    Diedrich, K
    GYNAKOLOGE, 2000, 33 (06): : 402 - 407
  • [25] Risk of breast cancer with hormone replacement therapy
    Michels, KB
    MIDLIFE HEALTH - CURRENT CONCEPTS AND CHALLENGES FOR THE FUTURE, 2002, 1229 : 135 - 141
  • [26] Hormone replacement therapy and risk of lymphomas and myelomas
    Altieri, A
    Gallus, S
    Franceschi, S
    Fernandez, E
    Talamini, R
    La Vecchia, C
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2004, 13 (04) : 349 - 351
  • [27] Hormone replacement therapy and the risk of breast cancer
    Cuzick, Jack
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (16) : 2344 - 2349
  • [28] Risk of hormone replacement therapy in stroke patients
    Damczyk, MP
    Gardner, DM
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2000, 25 (04) : 239 - 241
  • [29] Menopausal depression:comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine
    刘平
    何方方
    白文佩
    郁琦
    史蔚
    吴宜勇
    贺丹军
    肖计划
    郑晔
    廖秦平
    中华医学杂志(英文版), 2004, (02) : 31 - 36
  • [30] Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine
    Liu, P
    He, FF
    Bai, WP
    Yu, Q
    Shi, W
    Wu, YY
    He, DJ
    Xiao, JH
    Zheng, Y
    Liao, QP
    CHINESE MEDICAL JOURNAL, 2004, 117 (02) : 189 - 194